NCT06249633View on ClinicalTrials.gov

Inhaled Nitric Oxide for ARDS-related Pulmonary Hypertension

EARLY_PHASE1Not yet recruitingINTERVENTIONAL

Enrollment

20

Participants

Timeline

Start Date

February 29, 2024

Primary Completion Date

February 28, 2026

Study Completion Date

February 28, 2026

Conditions

Acute Respiratory Distress SyndromePulmonary Hypertension

Interventions

DRUG

Nitric Oxide

Inhaled nitric oxide

Trial Locations (1)

90048

Cedars-Sinai Medical Center, Los Angeles

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

Mallinckrodt

INDUSTRY

lead

Yuri Matusov

OTHER

NCT06249633 - Inhaled Nitric Oxide for ARDS-related Pulmonary Hypertension | Biotech Hunter | Biotech Hunter